China XLX Fertiliser Ltd. Beat Revenue Forecasts By 6.6%: Here's What Analysts Are Forecasting Next

Shareholders of China XLX Fertiliser Ltd. (HKG:1866) will be pleased this week, given that the stock price is up 11% to HK$11.47 following its latest half-yearly results. It was a workmanlike result, with revenues of CN¥16b coming in 6.6% ahead of expectations, and statutory earnings per share of CN¥0.75, in line with analyst appraisals. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on China XLX Fertiliser after the latest results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from China XLX Fertiliser's three analysts is for revenues of CN¥31.6b in 2026. This would reflect a solid 11% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to bounce 54% to CN¥1.33. In the lead-up to this report, the analysts had been modelling revenues of CN¥31.0b and earnings per share (EPS) of CN¥1.22 in 2026. So the consensus seems to have become somewhat more optimistic on China XLX Fertiliser's earnings potential following these results.

See our latest analysis for China XLX Fertiliser

The consensus price target rose 10% to HK$14.26, suggesting that higher earnings estimates flow through to the stock's valuation as well. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on China XLX Fertiliser, with the most bullish analyst valuing it at HK$14.50 and the most bearish at HK$14.12 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting China XLX Fertiliser's growth to accelerate, with the forecast 23% annualised growth to the end of 2026 ranking favourably alongside historical growth of 8.9% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.0% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that China XLX Fertiliser is expected to grow much faster than its industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards China XLX Fertiliser following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for China XLX Fertiliser going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - China XLX Fertiliser has 2 warning signs (and 1 which is potentially serious) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.